Moderna stock: Oddo BHF raises target for Moderna stock from USD 170 to USD 251

Published on 10/20/2026 at 16:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna will report third-quarter results on November 6, 2026. Moderna stock costs EUR 198.61 on October 20, 2026 at 4:02 p.m. CEST.

Target revision and reporting date

Oddo BHF lifted its target from USD 170.00 to USD 251.00 on October 19, 2026.
Second-quarter revenue reached USD 145.00 million, up 2.00 percent from the prior year.
Moderna stock costs EUR 198.61 at Lang & Schwarz on October 20, 2026 at 4:02 p.m. CEST.
Third-quarter results are scheduled for November 6, 2026.

Aquarellmalerei der Cambridge-Skyline mit modernen Forschungsgebäuden am Charles River — Moderna Inc. (US60770K1034) präsentiert eine stimmungsvolle Aquarell-Ansicht der Cambridge-Skyline mit modernen Biotech-Forschungsgebäuden am Flussufer, Illustration mit AI erstellt.

Moderna Inc. (ISIN US60770K1079) received a sharp analyst target increase from USD 170.00 to USD 251.00 on October 19, 2026, when Oddo BHF adjusted its view, according to Fidelity. At Lang & Schwarz, the stock was trading at EUR 198.61 on October 20, 2026 at 4:02 p.m. CEST.

USD 251 target versus the price

The new target stands 12.17 percent above Moderna's Nasdaq price of USD 223.77 on October 20, 2026 at 10:07 a.m. EDT. The same price was down 1.38 percent from the previous Nasdaq close of USD 226.89, placing the analyst revision against a softer intraday quote.

Revenue reached USD 145.00 million

Moderna reported USD 145.00 million in revenue for the second quarter of 2026, up 2.00 percent from USD 142.00 million in the second quarter of 2025. Its net loss was USD 782.00 million, an improvement of USD 43.00 million from the prior-year quarter, according to Yahoo Finance.

November 6 results date

Moderna announced on October 13, 2026 that it will report third-quarter 2026 financial results during an 8:00 a.m. ET conference call on November 6, 2026. The company also scheduled a corporate update for the same event, according to Newswire.

Comparison with peers

Quote data from October 20, 2026 place Moderna Inc. at minus 1.38 percent, a P/E of minus 27.97 and a market capitalization of USD 89.3 billion.

BioNTech (Nasdaq, USD): down 0.18 percent, P/E minus 11.73, market capitalization USD 22.4 billion. Pfizer (NYSE, USD): up 1.56 percent, P/E 39.51, market capitalization USD 170.4 billion.

Stock position and next step

Moderna's Nasdaq quote stood 7.64 percent below its 52-week high of USD 242.29 and 904.26 percent above its 52-week low of USD 22.28 on October 20, 2026 at 10:07 a.m. EDT. The company's biotechnology pipeline and its upcoming results date leave the USD 251.00 target as the clearest near-term valuation marker.

Moderna was trading at EUR 198.61 at Lang & Schwarz on October 20, 2026 at 4:02 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Moderna stock.